Jan. 28 at 1:36 PM
$RGNX- gap down to
$8.70, price alerts triggered & back on my DD list for some point
Pivotal DMD data in early Q2 (perhaps better safety & benefit vs
$SRPT Elevidys given inclusion of C-Terminal domain, to capture younger patient population)
Topline wet AMD data in Q4 (first GTx to make it to finish line)
Con side= farther down my queue due to regulatory risk (unpredictable FDA including on acceptance of biomarker endpoints, could do a 180 as with
$QURE,
$ATRA,
$REPL, etc)
